Zekuan Xu has completed his PhD at the age of 38 years from Nanjing Medical University. Now, he is the director of General Surgery, the First Affiliated Hospital of Nanjing Medical University. He has published more than 40 papers in reputed journals and has been serving as reviewers of Oncotarget, Tumor Biology and so on.
Objective The aim of this study was to investigate the safety and feasibility of laparoscopic uncut Roux-en-Y anastomosis in the distant gastrectomy for gastric cancer. Methods The clinical data of 92 patients performed laparoscopic uncut Roux-en-Y anastomosis in the Department of Gastric Surgery, the First Affiliated Hospital of Nanjing Medical University from June 2014 to June 2016 were analyzed retrospectively. Results The operations were performed successfully for all patients. The mean operation duration, anastomosis time, blood loss and the number of lymph nodes dissection during the surgery were (178.67±29.12) min, (30.84±7.41) min, (48.78±35.64) ml and 34.43±9.84 respectively. The time spent before gastrointestinal motility, liquid-diet intake, out-of-bed ambulation and the average hospitalization days after operation were (76.40±21.47) hours, (5.30±1.25) days, (48.14±20.25) hours and (9.19±3.09) days respectively. Postoperatively, 6 patients experienced complications, including gastrointestinal bleeding (2 patients), duodenal stump fistula (1 patient), Chylorrhea (1 patient)，Roux-Y stasis syndrome after gastrectomy (2 patients)，all of the complications were cured conservatively. None of the other complications occurred, such as anastomotic fistula, anastomotic stenosis, infection of incision, etc. Conclusion The laparoscopic uncut Roux-en-Y anastomosis is safe and feasible in the distant gastrectomy with D2 dissection for gastric cancer, with advantages of less trauma, faster recovery and so on.
Sylvia S. Sedhom was graduated from the faculty of Pharmacy, Ain shams University, has completed her Master’s degree at the age of 28 years from Ain Shams University. She works as a clinical pharmacist in the Pharmacology department in the National Research Centre, Cairo, Egypt. She has an interest in Research and has various presentations about different topics in clinical pharmacology.
Background: Non Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver injury. Elevated Uric acid (UA) is an important factor in the development of NAFLD. Both combined result in Apoptosis which is an important mechanism in pathogenesis of NAFLD, where it leads to activation of caspase family of intracellular proteases which then cleave different intracellular proteins including cytokeratin 18 (CK18) which can be used as a key marker in NAFLD. Objective: Evaluating the effect of treating hyperuricemia by allopurinol on NAFLD patients by blood markers as CK18, liver enzymes (GOT, GPT), Cholesterol (Chol) and Triglyceride (TG).Methods:31 hyperuricemic patients with NAFLD diagnosed by ultrasound were enrolled in the study and divided into two groups; Group A (14 patients): Placebo group who received starch based tablets for 3 months and Group B (17 patients): Treatment group who received allopurinol (300 mg) for 3 months. UA, CK 18, GPT, GOT, Chol and TG were measured before and after treatment.Results: The study showed a significant decline in CK18 levels after treatment (P=0.006), improvement in GPT and GOT levels after treatment (P<0.001 and P=0.013 respectively), also there was an improvement in Chol and TG levels after treatment (P= 0.01 and 0.038 respectively). Conclusion: Allopurinol may play a role in improvement of patients with NAFLD associated with hyperuricemia and CK18 may be used as a good marker in assessing patients’ improvement